AG-348 SAD: A Phase I Study of AG-348 in Healthy Volunteers

• Sponsor: Agios Pharmaceuticals, Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02108106
• Collaborator: (none)
• Enrollment: 48
• Location: 1
• Arms: 2
• Duration (Months): 5
• Patients Per Site Per Month: 9.5

Study Details

Study Description

Brief Summary

This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteer	Drug: AG-348; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 48 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers
• Study Start Date: Mar 1, 2014
• Actual Primary Completion Date: Aug 1, 2014
• Actual Study Completion Date: Aug 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: AG-348 Single oral dose of AG-348	Drug: AG-348; A range of doses of AG-348 will be tested based on assessment of safety and tolerability.; Other Names: AG-348 will be administered as a single oral dose on Day 1.
Placebo Comparator: Placebo Single oral dose of placebo	Drug: Placebo; Other Names: Placebo will be administered as a single oral dose on Day 1.

Outcome Measures

Primary Outcome Measures

1. Safety and tolerability [11 days]

   Incidence of adverse events and descriptive statistics for safety laboratory parameters, physical exam findings, vital signs and ECGs.

Secondary Outcome Measures

1. Pharmacokinetics of AG-348 [4 days]

   Descriptive statistics will be used to summarize PK parameters of AG-348 for each dose group and, where appropriate, for the entire population. Standard non-compartmental PK parameters will be calculated from individual plasma concentration data.

2. Pharmacodynamic (PD) relationship of AG-348 and metabolic biomarkers [4 days]

   The potential relationship between AG-348 and metabolic biomarkers will be explored with descriptive and graphical methods. Details on the evaluation of exploratory analyses of pyruvate kinase (PKR) activity and other potential PD biomarkers will be described.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 60 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Healthy adult male or female subjects 18 - 60 years, in good general health who are able to understand consent and complete all study procedures.

• Female subjects of non-child bearing potential (surgically sterile or post-menopausal as confirmed by age [over 50 years], amenorrhea for 12 consecutive months and FSH).

• Male subjects who are not vasectomized must agree to use contraception up to 30 days after dosing.

• Subjects with body weight ≥50 kg; BMI ≥18.5 and ≤32 kg/m2.

• Subjects who are non-smokers and have not used nicotine containing products for at least 3 months prior to screening.

• Subjects must be willing to refrain from caffeine- or xanthene containing products (chocolate) prior to dosing through 72 hours after dosing.

• Subjects must agree to refrain from strenuous exercise prior to admission through final visit.

• Subjects must refrain from use of alcohol starting 7 days prior to admission through final visit.

• Subjects must agree not to donate blood products for duration of study participation.

Exclusion Criteria:

• Subjects who have previously received AG-348.

• Subjects with clinically relevant screening laboratory tests.

• Female subjects of childbearing potential.

• Male subjects with QTcF interval ECG > 450 msec,or female subjects with QTcF interval ECG > 470 msec.

• Subjects with a history of a serious mental illness.

• Subjects with a clinically relevant medical history or pre-existing medical condition that would interfere with the absorption, metabolism or excretion of the study drug.

• Subjects with a history of any primary malignancy (cancer). Exceptions are certain skin cancers, cervical cancer in situ or other cancers that have been curatively treated without evidence of disease for a minimum of 1 year.

• Subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.

• Subjects who are positive for hepatitis B, hepatitis C or HIV.

• Subjects who have undergone surgery 6 months prior to screening.

• Subjects who have a history of illicit drug use or alcoholism within the last year.

• Subjects who are participating in other concurrent clinical trial of an investigational drug, or have received another investigational agent within the last 2 months.

• Subjects with any conditions which would make the subject unsuitable for enrollment, or could interfere with the subject's participation in or completion of the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1		Baltimore	Maryland	United States	21225

Sponsors and Collaborators

• Agios Pharmaceuticals, Inc.

Investigators

• Study Director: Samuel Agresta, MD, MPH & TM, Agios Pharmaceuticals, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Agios Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT02108106
• Other Study ID Numbers: AG348-C-001
• First Posted: Apr 9, 2014
• Last Update Posted: Oct 22, 2014
• Last Verified: Oct 1, 2014

• Keywords provided by Agios Pharmaceuticals, Inc.: safety and tolerability; pharmacokinetic study

Study Results

No Results Posted as of Oct 22, 2014